Create a narrative

Day One Biopharmaceuticals Community

NasdaqGS:DAWN Community

1 Narratives written by author
0 Comments on narratives written by author
8 Fair Values set on narratives written by author

Create a narrative

Day One Biopharmaceuticals

AN

AnalystConsensusTarget

AnalystConsensusTarget

Consensus Narrative from 8 Analysts

Pediatric Oncology Adoption And Pipeline Expansion Will Drive Future Success

Key Takeaways Expanding adoption of OJEMDA and a growing clinical pipeline position the company for sustained revenue growth and reduced reliance on a single product. International regulatory progress and strong payer support enable broader market access, improved margins, and financial flexibility for further investment.

US$26.25

FV

72.5% undervalued

36.05%

Revenue growth p.a.

0

0

6

3 days ago